Market Snapshot

S&P Futures
Dow Futures
NASDAQ Futures

Seres Therapeutics Inc. (MCRB) stock plunged in the premarket trading session; here’s why

Related Topics

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

It was observed in the last check, that Seres Therapeutics Inc. (MCRB stock) shares had plunged in the premarket trading session. The double-digit plunge had shed-58.09% off of the share price bringing it at $8.73 in pre-market. MCRB stock had closed the previous session on Thursday with a gain of 0.48% at $20.83. The MCRB stock volume traded 0.87 million shares, while in the past 50 days the average trade volume per day was around 0.87 million shares. In the past year up to date, MCRB shares have jumped by 338.53% and in the past week, the MCRB stock moved up by 1.61%. In the past three and six months, the stock has gained 1.66% and shed -17.99% respectively. Furthermore, the company is currently valued at $1.86 billion and has 91.53 million outstanding shares.

About Seres Therapeutics Inc.

Seres Therapeutics Inc. is a biotechnology company that specifically focuses on the development, discovery, and licensing of disease-treating therapeutics. The therapeutics is based on a microbiome platform that creates bacterial consortia. The bacterial consortia’s primary function is to interact with the host cells and tissues in a therapeutic way to treat the disease.

The organization’s lead item up-and-comer is the SER-109, an oral microbiome helpful competitor that has finished Phase III clinical preliminary for the treatment of clostridium difficile disease (CDI). It is likewise creating SER-287 that is in Phase IIb clinical preliminary to treat ulcerative colitis; SER-401, which is in Phase Ib clinical preliminary for use with designated spot inhibitors in patients with metastatic melanoma; and SER-301 that is in the Phase 1b clinical preliminary for the treatment of incendiary entrail sickness. What’s more, the organization participates in the improvement of SER-262 to treat an underlying repeat of CDI; and SER-155, a developed microorganisms microbiome drug intended to forestall mortality because of gastrointestinal contaminations, bacteremia, and join versus have illnesses in immunocompromised patients getting allogeneic hematopoietic undifferentiated cell transplantation and organ transfers.

The company’s platform and progress allows it to have licensing partnerships with other medical institutions and firms across the industry. It has made these sort of partnerships with Memorial Sloan Kettering Cancer Center and NestecLTd. The company was originally formed in 2010 by the name of Seres Health Inc. which was changed in May 2015. Furthermore, the headquarter of the company lies in Cambridge, Massachusetts.

MCRB stock is holding a meeting regarding the topline results of the phase 2b trial of ECO-RESET study

By Easter Time 8:30 am today, the MCRB stock had been hosting a conference call and live audio webcast. This conference was specifically hosted by the management team at Seres Therapeutics Inc. The main reason for hosting this live call and conference is to address the results from the phase 2b ECO-RESET study which had evaluated SER-287 in patients with mild-to-moderate ulcerative colitis (UC). The company provided topline results for this phase 2b study which listed that the Essential endpoint of clinical abatement contrasted with fake treatment was not accomplished; both dosing regimens of SER-287 were for the most part very much endured; open name and support parts of the SER-287 examination will be shut and Microbiome endpoints and examinations expected in the second 50% of 2021.

Leave a Comment

Your email address will not be published. Required fields are marked *

Sign up for our FREE Newsletter and get:

Latest Posts



Download Free eBook For


100% free. stop anytime no spam